

Variation in the financial calendar for year 2016

Milan (Italy), April 19, 2016 – With regard to the financial calendar published on January 27, 2016, MolMed S.p.A. (MLM.MI) hereby informs that **the board of director's meeting called to approve the interim financial report at March 31, 2016 will be held on May 10, 2016** instead of May 9, 2016 as previously indicated.

Please find here below the complete updated financial calendar for fiscal year 2016 (in pale grey the meetings already occurred).

Board of directors

DATE	SUBJECT
7 MARCH 2016	Approval of draft statutory financial statements for FY 2015
10 MAY 2016	Approval of interim financial report at 31/03/2016
1 ST AUGUST 2016	Approval of half-year financial report at 30/06/2016
7 NOVEMBER 2016	Approval of interim financial report at 30/09/2016

Shareholders' meeting

DATE	SUBJECT
18 APRIL 2016	Approval of statutory financial statements for FY 2015

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 patients treated to date; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquarter at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
 info@molmed.com - www.molmed.com

Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



COMUNICATO STAMPA

For further information:

Laura Villa

Investor Relations Director

MolMed S.p.A.

telefono: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com